Business
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 100% seizure reduction over time during 12-week double-blind periodLong-term data from the ongoing X-TOLE OLE study at 48 months show nearly 40% of participants achieving at least 12 months of seizure freedom and one in
About this update from Xenon Pharmaceuticals Inc.
[{"type":"image","alt":"Xenon Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Xenon Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/512e4110e9e95e88ef2c02e7ad2efa3b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s7o.0OXnOJy5uOTuo0NkvA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNA--/https://media.zenfs.com/en/globenewswire.com/512e4110e9e95e88ef2c02e7ad2efa3b","width":250,"height":80}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 100% seizure reduction over time during 12-week double-blind period","length":233,"tagName":"p"}]},{"val":[{"type":"text","content":"Long-term data from the ongoing X-TOLE OLE study at 48 months show nearly 40% of participants achieving at least 12 months of seizure freedom and one in four participants achieving at least 24 months of seizure freedom","length":218,"tagName":"p"}]},{"val":[{"type":"text","content":"Real-world data reinforce the value of anti-seizure medications that do not require titration to reduce stress and simplify focal seizure management for both patients and physicians","length":181,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":747,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Xenon is also presenting data at the AAN meeting that reinforce the significant opportunity for azetukalner in epilepsy, including 48-month data from the ongoing X-TOLE open-label extens...